AstraZeneca pauses £200m Cambridge expansion, dealing fresh blow to UK life sciences
Company says Cambridge project is 'paused' as pharmaceutical output falls and industry warns Britain risks becoming 'uninvestable'
AstraZeneca said it has paused a planned £200 million expansion at its Cambridge research site, a move that will halt the creation of about 1,000 jobs and sees none of the previously announced funding go ahead.
The company, Britain’s largest pharmaceutical firm, said the project — first announced in March 2024 — has been put on hold as it "constantly reassess[es] the investment needs of our company." The announcement came hours after Office for National Statistics data showed output from the pharmaceuticals industry in the UK fell 4.5% in July.
AstraZeneca’s statement did not specify a timeline for resuming the Cambridge work. The decision follows earlier reductions in planned UK investment: in January the company cancelled plans for a £450 million upgrade to its Merseyside vaccine manufacturing plant after a change in government support, and in recent days US drugmaker Merck (MSD) abandoned plans for a roughly £1 billion research centre in London.
Industry bodies said the series of decisions is a warning sign for the UK life sciences sector. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said recent ONS figures were "yet more cause for concern" as companies reassess UK investments and that there are "many warning lights flashing red for the UK's life sciences sector." He warned the situation will need close monitoring.
Executives from international drugmakers have pointed to the UK’s pharmaceutical pricing and rebate arrangements as a key factor influencing investment decisions. Under the current scheme, firms must repay 23.5% of sales to the National Health Service — a higher effective clawback than Germany’s roughly 7% or France’s less than 6%, industry sources say. Rippon Ubhi, speaking for Sanofi in comments reported by industry outlets, said the UK was increasingly being viewed in global boardrooms as "uninvestable" because of high clawback rates and constraints on patient access to new medicines.
AstraZeneca’s pause comes as the government seeks to attract private investment to boost economic growth. Ministers have repeatedly highlighted life sciences as a priority for regional jobs and innovation, while industry leaders have urged policy changes to improve the UK’s investment attractiveness.
The company’s latest move coincides with wider economic and political attention: the pause was announced days after Merck’s decision and ahead of high-profile international visits to the UK. Analysts said the clustering of investment reversals underscores broader investor caution in the sector.
AstraZeneca did not detail whether any parts of the Cambridge site will continue to operate or whether staff recruitment plans will be altered. The company’s research and development activities remain spread across multiple UK and global sites.
Government officials did not immediately respond to requests for comment on the impact of the paused investment. Industry groups have called for engagement between policymakers and companies to address the fiscal and regulatory factors that executives say are weighing on UK competitiveness. Observers said any change in investor sentiment could affect not only jobs and regional economies but also the UK’s long-term position in drug development and manufacturing.